Vivani Medical Q1 net loss $6.3M; secures $3M private placement; LIBERATE-1 data mid-2025

Vivani Medical, Inc.

2025-Q1 EPS reported -$0.11

Q1 net loss of $6.3M (vs $6.0M prior year); cash, equivalents & restricted cash $14.3M as of March 31.
Announced $3.0M private placement with Chairman Gregg Williams entity at $1.03/share (2.9M shares).
LIBERATE-1 Phase 1 study on track; all NPM-115 (exenatide) implant insertions successful; top-line results mid-2025.
Promising preclinical data for NPM-139 semaglutide implant for chronic weight management in obese/overweight.
Plans to spin off Cortigent brain implant division as an independent publicly traded company.

item 1.01 item 2.02 item 3.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.